Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues
作者:Sangwook Woo、Da-hye Kang、Jung Min Nam、Chong Soon Lee、Eun-Mi Ha、Eung-Seok Lee、Youngjoo Kwon、Younghwa Na
DOI:10.1016/j.ejmech.2010.06.017
日期:2010.9
etoposide at 100 μM concentration. In the DNA cross-linking test, compounds 20, 30 and 31 produced DNA cross-linked adducts and compound 30 was the strongest DNA cross-linker. Based on the combined pharmacological results, we suspected that the strong anti-cancer activity of compounds 16, 17, 20, 30 and 31 originated from the DNA mono-alkylation or cross-linking properties of the compounds.
为了开发对拓扑异构酶II和DNA起作用的潜在抗癌药,我们合成了12种新的黄酮酮衍生物。在细胞毒性测试中,化合物17和31对大多数测试的癌细胞系的抑制活性比阿霉素强2至7倍。卤代醇基团拴化合物19,21和27显示出相当的拓扑异构酶II依托泊苷抑制活性,在100μM浓度。在DNA交联测试中,化合物20,30和31产生的DNA交联的加合物和化合物30是最强的DNA交联剂。基于组合的药理学结果,我们怀疑化合物的强的抗肿瘤活性16,17,20,30和31源自所述化合物的DNA的单烷基化或交联性能。